Fig. 3: EGFR clustering-based screening for compounds in the FDA-approved library.

a EGF facilitated the formation of EGFR oligomers. Single-molecule images of EGFR showed brighter and larger fluorescent spots were increased as the EGF concentration increased. Single-molecule imaging began 1 min after the EGF addition. Scale bar, 2 μm. b The probability distribution of EGFR spot brightness. EGFR fractions shifted from small to large oligomers with higher EGF concentrations. c Effects of compounds on EGFR oligomerization were evaluated using the KLD (Kullback–Leibler divergence) of the brightness histograms before and after the compound treatment. Verteporfin exhibited high KLD values (red dot). d Verteporfin treatment increased the EGFR spots with lower brightness. e The probability distribution of EGFR spot brightness. The fraction of smaller EGFR oligomers was increased with verteporfin concentration, suggesting disassembly of the EGFR oligomers. f EGF (top), and verteporfin (bottom) dose-dependent KLD against the untreated condition. Data are presented as the mean ± SD from 4 independent experiments. g The dose-dependency was further evaluated by referring to MSD_167ms for verteporfin. Black circles denote MSD values without EGF, showing the reduction of MSD without EGF. Representative images from 4 independent experiments are displayed (a, d). Source data are provided as a Source Data file.